Bioarchitech, a pioneering company at the forefront of oncolytic virotherapy, joined industry leaders from around the globe at the 8th Annual Oncolytic Virotherapy Summit held from December 12-14, 2023, in Boston, Massachusetts.

One of the highlights of Bioarchitech’s participation was a presentation by Dr. William Jackson, the company's Head of Preclinical Development. Dr. Jackson’s talk, titled “Harnessing the Power of Viral Payloads for Optimal Delivery & Expression of Your OV Candidate,” drew significant interest as it addressed past and future challenges in viral payload engineering.

As Bioarchitech continues to lead in the integration of viral platforms with antibody therapies, Dr. Jackson underscored the importance of innovative and potent transgenes. He provided insights into Bioarchitech’s latest preclinical data, showcasing how engineered viruses could be harnessed to maximize therapeutic payload delivery, ultimately reducing off-target effects and enhancing tumor cell specificity. His presentation also highlighted ongoing collaborative studies, examining how these next-generation viral constructs interact synergistically with established antibody treatments.

Dr. Jackson’s presentation underscored Bioarchitech’s commitment to advancing cutting-edge, preclinical research that could soon transition into clinical applications, ultimately aiming to improve survival rates and quality of life for cancer patients worldwide.